LYNPARZA approved in the EU as adjuvant treatment for early breast cancer

First and only PARP inhibitor to improve invasive disease-free survival, the primary endpoint, and overall survival, a key secondary endpoint, in these patients

Merck KGaA posts higher earnings, profits across business segments

Despite the price increases for raw materials and logistics, EBITDA pre rose organically by 3.2% to € 1,782 million

PIB: Development of Ayush entrepreneurship

Ministry of Ayush signed a MoU with Ministry of Micro, Small & Medium Enterprises (MSME) for the promotion of Ayush enterprises.

Shivalik Rasayan Ltd inks marketing agreement with China Chinopharma

The CSC shall hold Market Authorisation (MA) to sell SRL's BUSALFAN, API exclusively in China territory.

Ensure time-bound Infrastructure development of Ayush National Institutes/Central Councils projects: Sonowal

Ministry of Ayush has fast tracked up-gradation and construction of various Ayush Infrastructure across the country

Statement from Krsnaa Diagnostics on IT survey

The news report stating Krsnaa Diagnostics has accepted Rs 100 crores of undisclosed income is incorrect and baseless.

Torrent Pharmaceuticals posts Q1FY23 consolidated PAT Rs. 354 Cr

Torrent Pharmaceuticals has reported total income of Rs. 2377 crores during the period ended June 30, 2022.

Dr. Reddy's Laboratories enters into a licensing agreement with Slayback Pharma

India has achieved replacement level fertility: Minister Pawar

Pawar also unveiled the India Family Planning 2030 vision document and launched the Medical Eligibility Criteria (MEC) Wheel Application, E-Module of Family Planning Logistics Management System (FPLMIS) and Digital Archive on Family Planning under the category of Digital Intervention.

Ascentage Pharma and Tanner Pharma Group initiate a global innovative named Patient Program

Tanner will be the supplier of olverembatinib to healthcare providers on a named patient basis in countries where the drug is not commercially available.